Payment overview · 2025
General Payments
$887.82
47 reported records · 15 companies
Healthcare provider profile · identity verified
Patrick Decourcy Walker, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HOUMA, LA · NPI 1780768630
Verified facts
What the public records show
CMS Open Payments records show Patrick Decourcy Walker, M.D. received $887.82 in general payments during 2025 across 47 reported records.
Lilly USA, LLC accounted for 17.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Mounjaro, Otezla, Trelegy Ellipta, Veozah, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 199 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Otezla by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Myrbetriq by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veozah as an associated drug or biological on 82795 records involving 35863 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Veozah by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 355 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 214 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 355 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $155.86 | 17.6% | 10 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $154.80 | 17.4% | 8 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $113.92 | 12.8% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $87.84 | 9.9% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $61.75 | 7.0% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $52.67 | 5.9% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $51.92 | 5.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $49.66 | 5.6% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $41.54 | 4.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.16 | 2.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.74 | 2.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.62 | 2.2% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $18.84 | 2.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.75 | 2.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.75 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $887.82 | 47 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $154.80 | 8 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $113.92 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $103.36 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $87.84 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $70.25 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $70.25 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $61.75 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $49.66 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $49.66 | 3 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $41.54 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $32.08 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $24.17 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $24.17 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.16 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $20.74 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.62 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.75 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.65 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 58 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 355 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 199 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 112 | exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 214 | exact normalized | Medicare Part D |
| Veozah veozah |
2025 | Veozah | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
199 | 56 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
94 | 21 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Veozah open payments reported associated product |
CMS Open Payments — General Payments 82795 supporting records · 35863 recipient NPIs · example record 1238560678 |
Veozah · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
58 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
355 | 58 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
214 | 48 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
355 | 58 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
112 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
61 | 17 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
80 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1242 | 149 |
| Atorvastatin Calcium | Atorvastatin Calcium | 880 | 203 |
| Eliquis | Apixaban | 702 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 656 | 157 |
| Gabapentin | Gabapentin | 647 | 145 |
| Amlodipine Besylate | Amlodipine Besylate | 640 | 148 |
| Trazodone Hcl | Trazodone Hcl | 537 | 114 |
| Furosemide | Furosemide | 444 | 95 |
| Clopidogrel | Clopidogrel Bisulfate | 437 | 84 |
| Tamsulosin Hcl | Tamsulosin Hcl | 422 | 98 |
| Levothyroxine Sodium | Levothyroxine Sodium | 401 | 81 |
| Quetiapine Fumarate | Quetiapine Fumarate | 401 | 73 |
| Jardiance | Empagliflozin | 355 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 351 | 71 |
| Sertraline Hcl | Sertraline Hcl | 330 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 326 | 96 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 325 | 87 |
| Memantine Hcl | Memantine Hcl | 312 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 310 | 61 |
| Metformin Hcl | Metformin Hcl | 309 | 73 |
| Lisinopril | Lisinopril | 291 | 64 |
| Ibuprofen | Ibuprofen | 288 | 91 |
| Losartan Potassium | Losartan Potassium | 279 | 72 |
| Carvedilol | Carvedilol | 253 | 55 |
| Duloxetine Hcl | Duloxetine Hcl | 234 | 40 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 232 | 69 |
| Mirtazapine | Mirtazapine | 221 | 30 |
| Prednisone | Prednisone | 218 | 95 |
| Ropinirole Hcl | Ropinirole Hcl | 218 | 47 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 214 | 48 |
| Diclofenac Sodium | Diclofenac Sodium | 212 | 73 |
| Meloxicam | Meloxicam | 212 | 49 |
| Linzess | Linaclotide | 199 | 56 |
| Tizanidine Hcl | Tizanidine Hcl | 197 | 68 |
| Metoprolol Tartrate | Metoprolol Tartrate | 195 | 58 |
| Omeprazole | Omeprazole | 192 | 46 |
| Ozempic | Semaglutide | 190 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 188 | 54 |
| Baclofen | Baclofen | 180 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 177 | 64 |
| Fluoxetine Hcl | Fluoxetine Hcl | 158 | 41 |
| Januvia | Sitagliptin Phosphate | 158 | 28 |
| Allopurinol | Allopurinol | 157 | 39 |
| Finasteride | Finasteride | 157 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 155 | 40 |
| Potassium Chloride | Potassium Chloride | 153 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 147 | 40 |
| Buspirone Hcl | Buspirone Hcl | 144 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 144 | 35 |
| Montelukast Sodium | Montelukast Sodium | 142 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 137 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 136 | 19 |
| Topiramate | Topiramate | 136 | 35 |
| Clonidine Hcl | Clonidine Hcl | 128 | 31 |
| Famotidine | Famotidine | 128 | 20 |
| Nifedipine Er | Nifedipine | 125 | 45 |
| Simvastatin | Simvastatin | 124 | 25 |
| Pregabalin | Pregabalin | 123 | 36 |
| Insulin Aspart Flexpen | Insulin Aspart | 118 | 26 |
| Megestrol Acetate | Megestrol Acetate | 115 | 39 |
| Amitriptyline Hcl | Amitriptyline Hcl | 114 | 24 |
| Tradjenta | Linagliptin | 113 | 13 |
| Mounjaro | Tirzepatide | 112 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 111 | 42 |
| Donepezil Hcl | Donepezil Hcl | 110 | 22 |
| Levetiracetam | Levetiracetam | 107 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 105 | 13 |
| Valsartan | Valsartan | 102 | 41 |
| Spironolactone | Spironolactone | 101 | 25 |
| Novolog Flexpen | Insulin Aspart | 100 | 25 |
| Myrbetriq | Mirabegron | 94 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 93 | 23 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 92 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 91 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 91 | 24 |
| Aripiprazole | Aripiprazole | 90 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 90 | 17 |
| Warfarin Sodium | Warfarin Sodium | 90 | 15 |
| Bupropion Xl | Bupropion Hcl | 89 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 89 | 14 |
| Xarelto | Rivaroxaban | 88 | 11 |
| Lovastatin | Lovastatin | 87 | 18 |
| Testosterone Cypionate | Testosterone Cypionate | 87 | 28 |
| Tramadol Hcl | Tramadol Hcl | 85 | 25 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 82 | 38 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 81 | 22 |
| Ondansetron Odt | Ondansetron | 81 | 21 |
| Entresto | Sacubitril/Valsartan | 80 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 79 | 16 |
| Naproxen | Naproxen | 79 | 24 |
| Alendronate Sodium | Alendronate Sodium | 77 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 75 | 19 |
| Glipizide | Glipizide | 75 | 24 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 74 | 23 |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 70 | 28 |
| Clonazepam | Clonazepam | 69 | 13 |
| Lurasidone Hcl | Lurasidone Hcl | 69 | 21 |
| Levemir Flexpen | Insulin Detemir | 65 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 65 | 12 |
| Primidone | Primidone | 65 | suppressed |
| Gemtesa | Vibegron | 64 | suppressed |
| Vascepa | Icosapent Ethyl | 63 | suppressed |
| Trulicity | Dulaglutide | 61 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 17 |
| Ezetimibe | Ezetimibe | 59 | 14 |
| Farxiga | Dapagliflozin Propanediol | 58 | 15 |
| Methocarbamol | Methocarbamol | 58 | 14 |
| Metformin Hcl Er | Metformin Hcl | 57 | 17 |
| Budesonide | Budesonide | 56 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 56 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 56 | 24 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 54 | 20 |
| Torsemide | Torsemide | 54 | 12 |
| Latanoprost | Latanoprost | 52 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 52 | 15 |
| Tresiba Flextouch U-200 | Insulin Degludec | 52 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 51 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 51 | suppressed |
| Alprazolam | Alprazolam | 50 | 12 |
| Midodrine Hcl | Midodrine Hcl | 50 | 12 |
| Colchicine | Colchicine | 49 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 49 | 23 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 48 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 47 | suppressed |
| Azithromycin | Azithromycin | 46 | 38 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 36 |
| Dexlansoprazole Dr | Dexlansoprazole | 44 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 43 | 11 |
| Meclizine Hcl | Meclizine Hcl | 43 | 17 |
| Timolol Maleate | Timolol Maleate | 43 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 36 |
| Risperidone | Risperidone | 42 | suppressed |
| Chlorthalidone | Chlorthalidone | 41 | 12 |
| Aptiom | Eslicarbazepine Acetate | 40 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 39 | suppressed |
| Lactulose | Lactulose | 39 | 20 |
| Solifenacin Succinate | Solifenacin Succinate | 39 | suppressed |
| Atenolol | Atenolol | 38 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 38 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 36 | 12 |
| Roflumilast | Roflumilast | 36 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 35 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 35 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 34 | 24 |
| Mupirocin | Mupirocin | 34 | 17 |
| Nitroglycerin | Nitroglycerin | 34 | 20 |
| Nystatin | Nystatin | 34 | 21 |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Vraylar | Cariprazine Hcl | 33 | suppressed |
| Olanzapine | Olanzapine | 32 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 31 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 15 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 30 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 30 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 29 | 23 |
| Fluconazole | Fluconazole | 29 | 21 |
| Hydrocortisone | Hydrocortisone | 29 | 16 |
| Lubiprostone | Lubiprostone | 29 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 29 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 29 | suppressed |
| Scopolamine | Scopolamine | 28 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 27 | 11 |
| Amantadine | Amantadine Hcl | 27 | suppressed |
| Digoxin | Digoxin | 27 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 27 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 27 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 26 | suppressed |
| Ketoconazole | Ketoconazole | 26 | 11 |
| Rasagiline Mesylate | Rasagiline Mesylate | 26 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 26 | suppressed |
| Valproic Acid | Valproic Acid | 26 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Otezla | Apremilast | 25 | suppressed |
| Rexulti | Brexpiprazole | 25 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 25 | suppressed |
| Lacosamide | Lacosamide | 24 | suppressed |
| Lidocaine | Lidocaine | 24 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 24 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 23 | 13 |
| Ibu | Ibuprofen | 23 | suppressed |
| Minoxidil | Minoxidil | 23 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 16 |
| Diazepam | Diazepam | 22 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 19 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 19 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Veozah | Fezolinetant | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Phenobarbital | Phenobarbital | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Dapsone | Dapsone | 14 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | suppressed |
| Neupro | Rotigotine | 14 | suppressed |
| Phenytoin | Phenytoin | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Entacapone | Entacapone | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Nystop | Nystatin | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Metaxalone | Metaxalone | 12 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Acamprosate Calcium | Acamprosate Calcium | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Mirabegron Er | Mirabegron | 11 | suppressed |
| Silodosin | Silodosin | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $887.82 · 47 records | Lilly USA, LLC | Auvelity, CAPLYTA, CREON, Dexcom G6 Transmitter, FARXIGA, INSPIRE, JARDIANCE, Kerendia, LEQVIO, LINZESS, MOUNJARO, OTEZLA, Ohtuvayre, QULIPTA, REPATHA, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Veozah, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error